Femasys reports 52% revenue growth in 2024; net loss widens to $18.8M; cash runway into Q3 2025

FEMASYS INC

Revenue $1.63M, up 52% YoY; net loss $18.8M ($0.85/sh) vs $14.2M ($0.93/sh) in 2023.
Cash $3.5M at year-end; subsequent $5.4M raise; expects runway into Q3 2025.
R&D $8.2M (+14%) and sales/marketing $4.0M (6x increase) due to FemBloc/FemaSeed launch.
FemBloc received European approval; partnerships with CNY Fertility, HRC Fertility, Boston IVF for FemaSeed.
CEO guides U.S. revenue to increase ~50% in Q1 2025 vs Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.